

# Scot H Simpson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7123739/scot-h-simpson-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94  
papers

3,676  
citations

29  
h-index

59  
g-index

105  
ext. papers

4,202  
ext. citations

3.5  
avg, IF

5.12  
L-index

#	Paper	IF	Citations
94	Foregone Opportunities? Time to Treatment Intensification Among Adults With Type 2 Diabetes and Elevated Glycated Hemoglobin on Metformin Monotherapy, 2009-2018.. <i>Canadian Journal of Diabetes</i> , <b>2022</b> , 46, 238-243.e4	2.1	
93	Effect of a pharmacy comprehensive chronic diseases care plan on use of lipid-lowering drugs among patients with hypertension. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2021</b> , 27, 426-434 <sup>1,9</sup>		
92	Depression and antecedent medication adherence in a cohort of new metformin users. <i>Diabetic Medicine</i> , <b>2021</b> , 38, e14426	3.5	0
91	Effect of a pharmacy comprehensive chronic diseases care plan on use of lipid-lowering drugs among patients with hypertension. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2021</b> , 27, 426-434 <sup>1,9</sup>		
90	Medication adherence in patients with mental illness and recent homelessness: contributing factors and perceptions on mobile technology use. <i>International Journal of Pharmacy Practice</i> , <b>2020</b> , 28, 362-369	1.7	1
89	Costarting sitagliptin with metformin is associated with a lower likelihood of disease progression in newly treated people with type 2 diabetes: a cohort study. <i>Diabetic Medicine</i> , <b>2020</b> , 37, 1715-1722	3.5	2
88	Concurrent use of opioids and benzodiazepines/Z-drugs in Alberta, Canada and the risk of hospitalisation and death: a case cross-over study. <i>BMJ Open</i> , <b>2020</b> , 10, e038692	3	3
87	Time to Treatment Intensification in Newly Treated Adult Type 2 Diabetes Patients: Comparison of Canada and the United States. <i>Canadian Journal of Diabetes</i> , <b>2020</b> , 44, 312-316	2.1	1
86	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update. <i>Canadian Journal of Diabetes</i> , <b>2020</b> , 44, 575-591	2.1	32
85	Factors associated with pneumococcal vaccination in 2040 people with type 2 diabetes: A cross-sectional study. <i>Diabetes and Metabolism</i> , <b>2020</b> , 46, 137-143	5.4	2
84	Optimal threshold of adherence to lipid lowering drugs in predicting acute coronary syndrome, stroke, or mortality: A cohort study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0223062	3.7	2
83	A Randomized Trial of Video-based Education in Patients With Heart Failure: The ongestive Heart Failure outreach program of ducation (COPE). <i>CJC Open</i> , <b>2019</b> , 1, 62-68	2	2
82	Evaluation of Healthy User Effects With Metformin and Other Oral Antihyperglycemia Medication Users in Adult Patients With Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , <b>2019</b> , 43, 322-328	2.1	4
81	Characterisation of concurrent use of prescription opioids and benzodiazepine/Z-drugs in Alberta, Canada: a population-based study. <i>BMJ Open</i> , <b>2019</b> , 9, e030858	3	10
80	Change in Trajectories of Adherence to Lipid-Lowering Drugs Following Non-Fatal Acute Coronary Syndrome or Stroke. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e013857	6	5
79	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. <i>Canadian Journal of Diabetes</i> , <b>2018</b> , 42 Suppl 1, S88-S103	2.1	108
78	Financial remuneration is positively correlated with the number of clinical activities: an example from diabetes management in Alberta community pharmacies. <i>International Journal of Pharmacy Practice</i> , <b>2018</b> , 26, 77-80	1.7	3

77	Knowledge of a Diabetes Risk Score Does Not Alter Diabetes Screening Practice in a Seniors Population: A Randomized Controlled Trial. <i>Journal of the American Medical Directors Association</i> , <b>2018</b> , 19, 1021-1023	5.9	1
76	Limited Effectiveness of Diabetes Risk Assessment Tools in Seniors Facility Residents. <i>Value in Health</i> , <b>2017</b> , 20, 329-335	3.3	4
75	Community Pharmacy-Based Inducement Programs Associated With Better Medication Adherence: A Cohort Study. <i>Annals of Pharmacotherapy</i> , <b>2017</b> , 51, 630-639	2.9	3
74	Provincial Comparison of Pharmacist Prescribing in Canada Using Alberta's Model as the Reference Point. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2017</b> , 70, 349-357	0.5	5
73	Factors Affecting Number of Diabetes Management Activities Provided by Pharmacists. <i>Canadian Journal of Diabetes</i> , <b>2016</b> , 40, 535-542	2.1	5
72	Text messaging interventions for individuals with mental health disorders including substance use: A systematic review. <i>Psychiatry Research</i> , <b>2016</b> , 243, 255-62	9.9	24
71	Medication Adherence Affects Risk of New Diabetes Complications: A Cohort Study. <i>Annals of Pharmacotherapy</i> , <b>2016</b> , 50, 741-6	2.9	25
70	Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2016</b> , 25, 1186-1195	2.6	12
69	Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , <b>2016</b> , 202, 126-30	3.2	7
68	Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study. <i>Diabetic Medicine</i> , <b>2016</b> , 33, 621-30	3.5	8
67	Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. <i>Canadian Journal of Diabetes</i> , <b>2016</b> , 40, 484-486	2.1	44
66	Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 523-532	6.7	53
65	Effect of an experiential exercise in diabetes management on pharmacy students' fear and perceived pain of injection and fingertip lancing. <i>American Journal of Pharmaceutical Education</i> , <b>2015</b> , 79, 05	2.5	
64	Mortality risk among sulfonylureas: a systematic review and network meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , <b>2015</b> , 3, 43-51	18.1	139
63	Pharmacists on primary care teams: Effect on antihypertensive medication management in patients with type 2 diabetes. <i>Journal of the American Pharmacists Association: JAPhA</i> , <b>2015</b> , 55, 265-8	1.7	7
62	Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial. <i>Diabetic Medicine</i> , <b>2015</b> , 32, 899-906	3.5	27
61	Creating a Data Analysis Plan: What to Consider When Choosing Statistics for a Study. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2015</b> , 68, 311-7	0.5	9
60	Applying new evidence into practice: a need for knowledge translation. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2015</b> , 68, 100-1	0.5	5

59	Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. <i>Journal of Diabetes and Its Complications</i> , <b>2015</b> , 29, 196-202	3.2	12
58	Limited impact of drug exposure misclassification from non-benefit thiazolidinedione drug use on mortality and hospitalizations from Saskatchewan, Canada: a cohort study. <i>Clinical Therapeutics</i> , <b>2015</b> , 37, 629-42	3.5	
57	Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin. <i>American Journal of Medicine</i> , <b>2014</b> , 127, 95.e1-9	2.4	25
56	Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study. <i>Diabetes, Obesity and Metabolism</i> , <b>2014</b> , 16, 22-9	6.7	15
55	Changes in thiazolidinedione use and outcomes following removal of a prior-authorization policy: controlled time-series analysis. <i>Medical Care</i> , <b>2014</b> , 52, 47-55	3.1	3
54	Feasibility of a self-administered survey to identify primary care patients at risk of medication-related problems. <i>Journal of Multidisciplinary Healthcare</i> , <b>2014</b> , 7, 123-7	2.8	9
53	Sex-based disparities in cardioprotective medication use in adults with diabetes. <i>Diabetology and Metabolic Syndrome</i> , <b>2014</b> , 6, 117	5.6	9
52	Diabetes that impacts on routine activities predicts slower recovery after total knee arthroplasty: an observational study. <i>Journal of Physiotherapy</i> , <b>2014</b> , 60, 217-23	2.9	13
51	Use patterns of antidiabetic regimens by patients with type 2 diabetes. <i>Canadian Journal of Diabetes</i> , <b>2013</b> , 37, 394-400	2.1	12
50	Adding pharmacists to primary care teams increases guideline-concordant antiplatelet use in patients with type 2 diabetes: results from a randomized trial. <i>Annals of Pharmacotherapy</i> , <b>2013</b> , 47, 43-8 <sup>2.9</sup>		13
49	Evaluating the introduction of a computerized prior-authorization system on the completeness of drug exposure data. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2013</b> , 22, 551-5	2.6	3
48	A systematic review of patient self-reported barriers of adherence to antihypertensive medications using the world health organization multidimensional adherence model. <i>Journal of Clinical Hypertension</i> , <b>2012</b> , 14, 877-86	2.3	98
47	Systematic Review of Pharmacist Interventions to Improve Adherence to Oral Antidiabetic Medications in People with Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , <b>2012</b> , 36, 292-299	2.1	36
46	Adding pharmacists to primary care teams reduces predicted long-term risk of cardiovascular events in type 2 diabetic patients without established cardiovascular disease: results from a randomized trial. <i>Diabetic Medicine</i> , <b>2012</b> , 29, 1433-9	3.5	27
45	Variations in tissue selectivity amongst insulin secretagogues: a systematic review. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 130-8	6.7	60
44	What elements of the patient-pharmacist relationship are associated with patient satisfaction?. <i>Patient Preference and Adherence</i> , <b>2012</b> , 6, 663-76	2.4	26
43	Of silos and systems: the issue of regionalizing health care. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2011</b> , 64, 237-40	0.5	7
42	Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. <i>Journal of General Internal Medicine</i> , <b>2011</b> , 26, 1336-44	4	35

41	Effect of adding pharmacists to primary care teams on blood pressure control in patients with type 2 diabetes: a randomized controlled trial. <i>Diabetes Care</i> , <b>2011</b> , 34, 20-6	14.6	80
40	Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. <i>Diabetes, Obesity and Metabolism</i> , <b>2010</b> , 12, 47-53	6.7	91
39	Exploring patients' perceptions for insulin therapy in type 2 diabetes: a Brazilian and Canadian qualitative study. <i>Patient Preference and Adherence</i> , <b>2010</b> , 4, 171-9	2.4	9
38	A discrete choice experiment evaluation of patients' preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management. <i>Patient Preference and Adherence</i> , <b>2010</b> , 4, 433-40	2.4	24
37	Evidence to support development of pharmacy services: how much or how little do we need?. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2010</b> , 63, 97-102	0.5	0
36	Aspirin Use Rates in Diabetes: A Systematic Review Cross-Sectional Study. <i>Canadian Journal of Diabetes</i> , <b>2010</b> , 34, 211-217	2.1	4
35	Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. <i>American Journal of Medicine</i> , <b>2010</b> , 123, 47-53	2.4	58
34	Socioeconomic differences in preferences and willingness-to-pay for insulin delivery systems in type 1 and type 2 diabetes. <i>Diabetes Technology and Therapeutics</i> , <b>2009</b> , 11, 567-73	8.1	20
33	A valuation of patients' willingness-to-pay for insulin delivery in diabetes. <i>International Journal of Technology Assessment in Health Care</i> , <b>2009</b> , 25, 359-66	1.8	30
32	Evaluation of attitudes and perceptions of key clinical stakeholders regarding out-of-hospital diagnosis and treatment of ST elevation myocardial infarction patients using a region-wide survey. <i>Emergency Medicine Journal</i> , <b>2009</b> , 26, 371-6	1.5	2
31	Survey of Pharmacist Activities and Attitudes in Diabetes Management. <i>Canadian Pharmacists Journal</i> , <b>2009</b> , 142, 128-134.e2	1.3	13
30	Hypertension treatment and control rates: chart review in an academic family medicine clinic. <i>Canadian Family Physician</i> , <b>2009</b> , 55, 735-41	0.9	10
29	Enhancing hypertension awareness and management in the elderly: lessons learned from the Airdrie Community Hypertension Awareness and Management Program (A-CHAMP). <i>Canadian Journal of Cardiology</i> , <b>2008</b> , 24, 561-7	3.8	25
28	The darkening cloud of diabetes: do trends in cardiovascular risk management provide a silver lining?. <i>Diabetes Care</i> , <b>2008</b> , 31, 2136-42	14.6	7
27	Pharmacist care of patients with heart failure: a systematic review of randomized trials. <i>Archives of Internal Medicine</i> , <b>2008</b> , 168, 687-94		215
26	Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis. <i>Open Medicine</i> , <b>2008</b> , 2, e26-38		1
25	Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes: a population-based cohort study. <i>Stroke</i> , <b>2007</b> , 38, 1739-43	6.7	57
24	Comment on: Evans JM, Ogston SA, Emslie-Smith A, Morris A (2006) risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. <i>Diabetologia</i> 49:930-936. <i>Diabetologia</i> , <b>2006</b> , 49, 2805-6	10.3	2

23	Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. <i>Cmaj</i> , <b>2006</b> , 174, 169-74	3.5	165
22	The natural history of LDL control in type 2 diabetes: a prospective study of adherence to lipid guidelines. <i>Diabetes Care</i> , <b>2006</b> , 29, 2506-8	14.6	3
21	A meta-analysis of the association between adherence to drug therapy and mortality. <i>BMJ, The</i> , <b>2006</b> , 333, 15	5.9	787
20	Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies. <i>Canadian Journal of Cardiology</i> , <b>2006</b> , 22, 855-60	3.8	39
19	Angiotensin receptor blockers and risk of myocardial infarction: systematic review. <i>BMJ, The</i> , <b>2005</b> , 331, 873	5.9	53
18	Do guidelines guide pneumonia practice? A systematic review of interventions and barriers to best practice in the management of community-acquired pneumonia. <i>Respiratory Care Clinics of North America</i> , <b>2005</b> , 11, 1-13		39
17	Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. <i>Diabetic Medicine</i> , <b>2005</b> , 22, 497-502	3.5	119
16	Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus. <i>Pharmacotherapy</i> , <b>2005</b> , 25, 810-6	5.8	40
15	Physician Perceptions of Enhanced Community Pharmacist Care in Cholesterol Management: A Survey of Physicians Contacted during the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). <i>Canadian Pharmacists Journal</i> , <b>2005</b> , 138, 33-39	1.3	3
14	Barriers to General Practitioner Participation in a Clinical Trial Initiated by Pharmacists: Reluctance Stemmed Largely from Concerns over Liability. <i>Canadian Pharmacists Journal</i> , <b>2005</b> , 138, 52-60	1.3	
13	Development of educational materials for congestive-heart-failure patients. <i>American Journal of Health-System Pharmacy</i> , <b>2004</b> , 61, 386-9	2.2	3
12	Statin use in Type 2 diabetes mellitus is associated with a delay in starting insulin. <i>Diabetic Medicine</i> , <b>2004</b> , 21, 962-7	3.5	17
11	Greater effect of enhanced pharmacist care on cholesterol management in patients with diabetes mellitus: a planned subgroup analysis of the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). <i>Pharmacotherapy</i> , <b>2004</b> , 24, 389-94	5.8	21
10	Physician-perceived barriers to adopting a critical pathway for unity-acquired pneumonia. <i>Joint Commission Journal on Quality and Safety</i> , <b>2004</b> , 30, 387-95		16
9	The cost of major comorbidity in people with diabetes mellitus. <i>Cmaj</i> , <b>2003</b> , 168, 1661-7	3.5	35
8	Development and validation of a survey to assess barriers to drug use in patients with chronic heart failure. <i>Pharmacotherapy</i> , <b>2002</b> , 22, 1163-72	5.8	25
7	A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). <i>Archives of Internal Medicine</i> , <b>2002</b> , 162, 1149-55		204
6	Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. <i>Diabetes Care</i> , <b>2002</b> , 25, 2244-8	14.6	334

5	Economic impact of community pharmacist intervention in cholesterol risk management: an evaluation of the study of cardiovascular risk intervention by pharmacists. <i>Pharmacotherapy</i> , <b>2001</b> , 21, 627-35	5.8	33
4	Practice-based research: lessons from community pharmacist participants. <i>Pharmacotherapy</i> , <b>2001</b> , 21, 731-9	5.8	41
3	Using focus groups to identify barriers to drug use in patients with congestive heart failure. <i>Pharmacotherapy</i> , <b>2000</b> , 20, 823-9	5.8	35
2	Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): a randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk. <i>Annals of Pharmacotherapy</i> , <b>1999</b> , 33, 910-9	2.9	45
1	Possible adverse skin reaction to carvedilol. <i>Canadian Journal of Cardiology</i> , <b>1998</b> , 14, 1277-9	3.8	1